A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe

BACKGROUND: Bone metastases (BMs) are common in patients with prostate cancer and can lead to skeletal-related events (SREs), which are associated with increased pain and reduced quality of life (QoL). Bone-targeted agents (BTAs), such as zoledronic acid and denosumab, reduce the incidence of SREs a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Bone Oncol
Autori principali: Body, Jean-Jacques, von Moos, Roger, Rider, Alex, Hallworth, Pamela, Bhowmik, Debajyoti, Gatta, Francesca, Hechmati, Guy, Qian, Yi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2018
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6319023/
https://ncbi.nlm.nih.gov/pubmed/30627511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2018.100212
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi